| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
PEG2000‑DMPE does not have a specific biological receptor target but serves as a surface functionalization material. The DMPE lipid anchor inserts into lipid bilayers, while the PEG chain forms a hydrophilic "protective shell" that reduces non‑specific protein adsorption and prolongs circulation time. The compound is used to synthesize lipid nanoparticles (LNPs) and enhances encapsulation efficiency depending on the proportion of PEG2000‑DMPE in the liposome formulation.
|
|---|---|
| ln Vitro |
In vitro, PEG2000‑DMPE is used to synthesize LNPs and liposomes for drug delivery applications. It enhances the entrapment efficiency of liposomes, with the optimal formulation for animal studies being DMPC/PEG2000‑DMPE/CH = 50/5/45 at a drug/lipid weight ratio of 1/20. The PEG chain provides a steric barrier that prevents aggregation and non‑specific binding.
|
| ln Vivo |
In vivo, PEG2000‑DMPE‑containing liposomes exhibit prolonged circulation time due to the PEG "protective shell" that reduces opsonization and clearance by the reticuloendothelial system. The compound is used to construct "stealth" liposomes, enhancing the in vivo stability and biocompatibility of drug carriers. It is widely used in drug delivery, bioimaging, and tissue engineering applications.
|
| Enzyme Assay |
Non‑cellular assays for PEG2000‑DMPE typically involve characterizing its ability to form liposomes and LNPs. Liposome formation can be assessed by dynamic light scattering (DLS) to measure particle size and polydispersity. Encapsulation efficiency is measured by encapsulating a model drug and quantifying the amount encapsulated. The steric barrier effect of the PEG chain can be assessed by measuring protein adsorption.
|
| Cell Assay |
In vitro cellular assays for PEG2000‑DMPE involve treating cells with PEG2000‑DMPE‑containing liposomes or LNPs to assess cellular uptake, cytotoxicity, and drug delivery efficiency. Cellular uptake of fluorescently labeled liposomes can be quantified by flow cytometry or fluorescence microscopy. Cytotoxicity is assessed using standard assays such as MTT.
|
| Animal Protocol |
In vivo animal experiments for PEG2000‑DMPE involve administering PEG2000‑DMPE‑containing liposomes or LNPs to animal models to evaluate biodistribution, pharmacokinetics, and therapeutic efficacy. The optimal formulation for animal studies is DMPC/PEG2000‑DMPE/CH = 50/5/45 at a drug/lipid weight ratio of 1/20. Endpoints include tissue distribution, circulation half‑life, and therapeutic outcomes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for PEG2000‑DMPE are influenced by the properties of the liposomes or LNPs formed. The PEG chain prolongs circulation time by reducing opsonization and clearance by the reticuloendothelial system. The compound is typically supplied as a white powder, soluble in organic solvents and aqueous systems, and should be stored protected from light, sealed, and dry to prevent PEG chain degradation and lipid oxidation.
|
| Toxicity/Toxicokinetics |
Toxicological data for PEG2000‑DMPE are limited. PEGylated phospholipids are generally considered biocompatible and non‑toxic at concentrations used in research applications. PEG is widely used in FDA‑approved pharmaceutical formulations. The compound is intended for research use only and not for human consumption. Standard safety precautions for handling lipid reagents apply.
|
| References | |
| Additional Infomation |
PEG2000‑DMPE is an amphiphilic PEGylated phospholipid consisting of DMPE covalently linked to PEG (MW ~2000). It is widely used in the biomedical field for drug delivery, bioimaging, and tissue engineering. It enhances the entrapment efficiency of liposomes and is used to synthesize LNPs. The optimal formulation for animal studies is DMPC/PEG2000‑DMPE/CH = 50/5/45 at a drug/lipid weight ratio of 1/20. It is supplied for research purposes only.
|
| Molecular Formula |
C37H72NO11P
|
|---|---|
| Molecular Weight |
2676.25
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~37.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (0.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (0.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (0.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3737 mL | 1.8683 mL | 3.7366 mL | |
| 5 mM | 0.0747 mL | 0.3737 mL | 0.7473 mL | |
| 10 mM | 0.0374 mL | 0.1868 mL | 0.3737 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
